Seeking Alpha

Cubist continues to rally

  • Shares of Cubist Pharmaceuticals (CBST +4.9%) are up handsomely again today, adding to gains posted Wednesday following the company's acquisitions of Trius and Optimer. (previous coverage)
  • Aegis Capital upgrades CBST to Buy.
  • Jefferies ups the price target on CBST to $70 from $64. Acquisitions should increase earnings in FY14, 15, and 16 by 7%, 13%, and 17% respectively, analyst Eun Yang says.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs